ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
Jennifer Morrell-Falvey’s interest in visualizing the science behind natural processes was what drew her to ORNL in what she expected to be a short stint some 18 years ago.
ORNL, TVA and TNECD were recognized by the Federal Laboratory Consortium for their impactful partnership that resulted in a record $2.3 billion investment by Ultium Cells, a General Motors and LG Energy Solution joint venture, to build a battery cell manufacturing plant in Spring Hill, Tennessee.
Researchers at Oak Ridge National Laboratory are using a novel approach in determining environmental impacts to aquatic species near hydropower facilities, potentially leading to smarter facility designs that can support electrical grid reliability.
Ten scientists from the Department of Energy’s Oak Ridge National Laboratory are among the world’s most highly cited researchers, according to a bibliometric analysis conducted by the scientific publication analytics firm Clarivate.
Scientists at ORNL and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in
The Department of Energy’s Office of Science has selected five Oak Ridge National Laboratory scientists for Early Career Research Program awards.
Belinda Akpa is a chemical engineer with a talent for tackling big challenges and fostering inclusivity and diversity in the next generation of scientists.
Rich Giannone uses bioanalytical mass spectrometry to examine proteins, the primary driver in biological systems.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.